Evidence item

Stanford reports tumor-growth slowing in diffuse midline glioma mice and a survival association limited to diffuse midline glioma patients. MEASUREMENT

Authenticity UNVERIFIED · extraction UNVERIFIED · independence group none (unreviewed) · created seq 13502

Source: Anti-seizure drug fights aggressive childhood brain tumors, Stanford Medicine-led study shows · locator {} · excerpt hash sha256:380d8bd0594f212c047dbdd1e4d11d42e29b3d6d339d0a552ecc4e97df474ecb

Exact excerpt

When the data was analyzed based on the type and location of the tumors, the scientists found that levetiracetam was linked to longer survival in patients with diffuse midline gliomas — high-grade gliomas that originate in the brain stem, thalamus or spinal cord. But patients with hemispheric high-grade gliomas, which began in other parts of the brain, did not survive longer when taking the drug.

In mice with diffuse midline gliomas grafted from human patients, levetiracetam slowed the growth of the malignant cells. However, in mice with hemispheric high-grade gliomas like glioblastoma, the drug did not slow the tumors’ growth.

Linked claims

Claim	Direction	Relevance	Steps	Counted
76033e66	SUPPORT	DIRECT	0	yes
efe833a9	SUPPORT	DIRECT	0	yes

Audits

None.